| |
Intervention group (n=61) |
Control group (n=107) |
Mean Difference
(95% CI) |
Standard Error |
t-statistic |
P value |
| Conditional Estimates |
|
|
|
|
|
|
| Duration of ART |
|
|
|
|
|
|
| MPR if ART ± 995 days (n) |
97%
(31) |
98%
(53) |
-1.1%
(-2.5 , 2.3) |
0.01 |
-0.11 |
0.91 |
| MPR if ART <995 days (n) |
98%
(37) |
84%
(53) |
14.5%
(6.3 , 22.7) |
0.04 |
3.46 |
<0.01 |
| MPR if ART ± 154 days (n) |
98%
(61) |
89%
(107) |
9.5%
(4.9, 14) |
0.02 |
4.06 |
<0.01 |
| MPR if ART ± 230 days (n) |
99%
(60) |
88%
(103) |
10.7%
(6.3, 15) |
0.02 |
4.71 |
<0.01 |
| MPR if ART ± 231 days (n)* |
99%
(60) |
98%
(101) |
0.6%
(-2.1, 3) |
0.01 |
0.42 |
0.67 |
| MPR if ART ± 250 days (n) |
99%
(59) |
98%
(98) |
0.05%
(-1.2, 2) |
0.009 |
0.06 |
0.95 |
| Baseline BMI, kg/m2 |
|
|
|
|
|
|
| MPR if BMI is <18.5 (n) |
99%
(12) |
66%
(15) |
33.3%
(10.8 , 55.9) |
0.12 |
2.9 |
<0.01 |
| MPR if BMI is ± 18.5 (n) |
98.35%
(45) |
98.32%
(92) |
0.03%
(-0.019 , 0.02) |
`0.01 |
0.03 |
0.98 |
| Baseline Stage of Disease |
|
|
|
|
|
|
| MPR if HIV disease stage I or II (n) |
99%
(31) |
98%
(68) |
0.8%
(-2.6 , 4.1) |
0.02 |
0.45 |
0.65 |
| MPR if HIV disease stage III or IV (n) |
99%
(15) |
78%
(19) |
20.9%
(-2.8 , 44.6) |
0.12 |
1.73 |
0.09 |
| Baseline CD4 count, , mean cells/μl |
|
|
|
|
|
|
| MPR if CD4+lymphocyte count <350 (n) |
99%
(24) |
80%
(44) |
18.9%
(10.8 , 27.0) |
0.04 |
4.57 |
<0.01 |
| MPR if CD4+ lymphocyte count >350 (n) |
98%
(44) |
94%
(63) |
4.8%
(1.8 , 7.7) |
0.02 |
3.19 |
<0.01 |
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; MPR, medication possession ratio. Total N for matching is 175 reduced to 168 observations after
imposing common support (7 treated cases not on support). Overall estimates, N=61 (intervention), 107 (control).
*Difference in MPR between arms was no longer significant when participants with >230 days of ART or greater were included in the analysis. |
